I am ambivalent on this news. Great to see another company bringing immunotherapy to market.
http://www.stockmarketsreview.com/news/220711/
But essentialy as DCVax may also target ovarian cancer they may be our competitors in the future as well.
Another one to watch for progress.....
And another thought that crosses my mind if eventually this type of therapy becomes more commonly prescribed for various types of malignant cell growth at differing stages of diagnosis one would think the number of providers of the vaccine would also increase leading to greater competition and lower prices for the patient????
Only time will tell on this one I guess.....
more competition in the us dcvax
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $435.7M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.5¢ | 28.5¢ | $469.8K | 1.579M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 297652 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 7500 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |